Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22787169 | 0.85 | TDP1 (0.33) | ALDH1A1TP53TSHR | |
| SCHEMBL24322914 | 0.80 | ALDH1A1 (0.30) | ALDH1A1TP53TSHR | |
| SCHEMBL22787160 | 0.78 | ALDH1A1 (0.39) | ALDH1A1TSHR | |
| SCHEMBL20334057 | 0.78 | — | — | |
| SCHEMBL20334056 | 0.78 | — | — | |
| SCHEMBL22787177 | 0.78 | CRBN (0.35) | ALDH1A1TSHR | |
| SCHEMBL12657792 | 0.74 | — | — | |
| SCHEMBL12677130 | 0.72 | — | — | |
| SCHEMBL19252632 | 0.70 | — | — | |
| SCHEMBL19252673 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210102205-A1 | EXON SKIPPING OLIGOMERS AND OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2021-04-08 | — | — | US | disclosed |
| US-20200392503-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE | Regulus Therapeutics Inc. (US) | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392503-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE | PKD1, PKD2, PCSK7 | ALDH1A1 4618/4885TP53 149/4885TSHR 4711/4885 |
| US-20210102205-A1 | EXON SKIPPING OLIGOMERS AND OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | UTRN, RBM17, UPF1 | ALDH1A1 4469/4885TP53 3747/4885TSHR 4424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.